Twist Bioscience

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期三, 五月 15, 2024
TWIST, IVDR, Partnership, Hereditary angioedema, DSM-IV codes, LRRK2, Genetic testing, Software, Cancer, Parkinsonism, Total, European, Drug discovery, RNA, Twist Bioscience, Disclosure, Mox, Niemann–Pick disease, CLN6, Sale, Whole genome sequencing, Publication, Epilepsy, Physician, Frontotemporal dementia, DNA sequencing, JV, CFTR, FTD, Elbow method (clustering), Disease, CNTG, Research, Observational study, Patient, Genetics, Gulf Cooperation Council, Sequence, CE, DNA, Therapy, Acyl-CoA, Software as a service, GCC, Growth, Gaucher's disease, Spinal muscular atrophy, Fine chemical

and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.
  • We expanded our partnership model with a joint venture in Saudi Arabia, securing a $30 million investment and additional milestone payments.
  • With this progress at the forefront, CENTOGENE is positioned for growth and a path towards profitability.
  • There can be no assurance that our strategic review process will result in any transaction or other strategic outcome.

The Global Biomanufacturing Market Report 2024-2035, with Profiles of 1000+ Companies at the Forefront of Biomanufacturing Innovation - ResearchAndMarkets.com

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, Pharmaceutical, Health, Paper, Food, Vaccine, Detergent, Biomanufacturing, N-terminal telopeptide, Twist Bioscience, Metabolism, Biofuel, Fermentation, Polymer, A-DNA, Textile, Evolutionism, Enzyme, Agriculture, Aviation biofuel, Plastic, Fine chemical

The Global Biomanufacturing Markets 2024-2035 is a comprehensive market report that explores the rapidly evolving landscape of biomanufacturing technologies and applications.

Key Points: 
  • The Global Biomanufacturing Markets 2024-2035 is a comprehensive market report that explores the rapidly evolving landscape of biomanufacturing technologies and applications.
  • The report offers a detailed overview of biomanufacturing processes, technologies, and host organisms, highlighting the importance of this industry in the global economy.
  • The biomanufacturing market is a rapidly growing sector that involves the production of various products using biological systems, such as living cells, enzymes, or other biological components.
  • The report features profiles of over 1,000 companies at the forefront of biomanufacturing innovation, offering valuable insights into their technologies, products, and strategic initiatives.

Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine

Retrieved on: 
星期三, 五月 22, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Other Science, Research, Data Analytics, Software, Genetics, Science, Dark, Oxford Nanopore Technologies, NGS, Doctor of Philosophy, Twist, CYP2D6, Medicine, Twist Bioscience, Gene

Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.

Key Points: 
  • Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
  • The beta program aims to increase the diversity of genetic variants evaluated by Oxford Nanopore’s platform.
  • “Our collaboration with Twist Bioscience underscores our commitment to advancing the possibility of personalised medicine through PGx by providing unambiguous genetic results in a single assay,” said Gordon Sanghera, CEO of Oxford Nanopore.
  • “The exceptional uniformity of our sequencer agnostic workflows enables researchers around the world to advance scientific breakthroughs.”
    For more information about the PGx Beta Program and other innovations from Oxford Nanopore Technologies, visit https://nanoporetech.com .

Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications

Retrieved on: 
星期一, 五月 13, 2024
Technology, Research, Genetics, Other Technology, Nanotechnology, Biotechnology, Health, Other Science, Science, CRISPR, DNA, Doctor of Philosophy, Silicon, Twist Bioscience, Protein engineering, Twist, Passenger name record, Fine chemical

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.
  • “Using our chemical synthesis platform we are able to directly synthesize Twist Multiplexed Gene Fragments as fragment pools of up to 500 bp in length.
  • By offering Twist's high-quality gene fragments in a pooled format at prices that scale with the number of sequences, Twist is enabling customers to conduct applications that may have been previously unfeasible or cost-prohibitive, facilitating high-throughput screening in a way that is far more accessible to researchers across industry segments,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Twist Multiplexed Gene Fragments are pools of customizable double-stranded DNA (dsDNA) between 301-500 base pairs in length.

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 2, 2024
Technology, Biotechnology, Nanotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, General Health, Genetics, Health Technology, Science, Data Management, Twist, Doctor of Philosophy, Nucleic acid thermodynamics, Net, Genomics, Investment, Exome, Capital, Sequence, PIN, Depreciation, Silicon, Genetic variation, Growth, Twist Bioscience, NGS, Development, Administration, SynBio, Tax, UHT, Adjustment, Telephone, GAAP, Element, Gene, Tobacco

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.
  • Shipped products to 2,253 customers in the second quarter of fiscal 2024, compared to approximately 2,100 customers in the second quarter of fiscal 2023.
  • Shipped approximately 193,000 genes during the second quarter of fiscal 2024, compared with approximately 152,000 genes during the second quarter of fiscal 2023.
  • For the third quarter of fiscal year 2024, Twist provided the following financial guidance:
    For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:
    1For in vitro diagnostic use.

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

Retrieved on: 
星期四, 三月 28, 2024
Research, Technology, Semiconductor, Genetics, Nanotechnology, Biotechnology, Hardware, Health, Data Management, Science, Genetic variation, Panel, NHGRI, Twist Bioscience, Twist, WES, Genome, Doctor of Philosophy, Sequence, Production, Exome, Silicon

In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • “When companies such as Twist utilize our reference standard to create research tools, it facilitates scientists’ study of genetic variation.
  • The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of pangenome variants and can be spiked into the Twist Exome 2.0 to target more than 94% of the novel pangenome variants affecting coding sequences in the exome.
  • If interested in the Human Pangenome Spike-in Panel for the Twist Exome 2.0 panel, please complete the contact form here: https://www.twistbioscience.com/contact

Breakout Ventures Welcomes Five New Venture Partners

Retrieved on: 
星期二, 三月 26, 2024
Biotechnology, Health, Finance, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, Start-Up, Data Analytics, Genetics, Health Technology, Science, Clinical Trials, HTP, Genomics, University of Cambridge, Ashland Global, UCSF, Data science, Twist Bioscience, Walter, MIT, Synthetic biology, Cell biology, UC, University, Software, Doctor of Philosophy, Elemental Machines, University of Michigan, Marshall Scholarship, Pleasure, Silicon, Biochemistry, Investment, Therapy, Ilan, Drug development, Multimedia, Coco, University of California, Berkeley, Management

Breakout Ventures , the home for creative bioscience entrepreneurs, is pleased to welcome five new venture partners.

Key Points: 
  • Breakout Ventures , the home for creative bioscience entrepreneurs, is pleased to welcome five new venture partners.
  • Walter advises numerous portfolio companies of VC and PE firms, including as a board member for Checkerspot, a Breakout Ventures investment.
  • Breakout supports our portfolio companies with more than just capital, and we are excited to welcome this group of insightful leaders.
  • To learn more about Breakout Ventures, visit: https://www.breakout.vc/ .

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

Retrieved on: 
星期二, 三月 5, 2024
Research, Other Health, Pharmaceutical, Technology, Medical Devices, Genetics, Health Technology, Science, Nanotechnology, Biotechnology, Medical Supplies, Health, Other Science, Twist Bioscience, Twist, Reagent, Silicon, IVDR, NGS, Documentation, Doctor of Philosophy, Safety, Certification, Exon, Genome, Laboratory, DNA, IVD, Workflow, Medical device

The suite of our CE-marked Products includes:

Key Points: 
  • The suite of our CE-marked Products includes:
    The Twist Precision Prep and Enrichment Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment), which is panel-agnostic2
    Twist Precision Exome Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment along with targeted capture probes for exome enrichment; IVDR compliant workflow)
    The Twist Precision Prep and Enrichment Dx Kit and the Twist Precision Exome Dx Panel can be used individually within existing workflows or as a combined solution known as the Twist Precision Exome Dx Kit.
  • “The Twist Precision Dx products are our first NGS product line specifically developed to be included within regulated customer products.
  • The Twist Precision Exome Dx Panel1 is a qualified Twist DNA panel that can be used in conjunction with the Twist Precision Prep and Enrichment Dx kit to produce exome-enriched libraries compatible for NGS applications.
  • Twist Precision Exome Dx Kit1 utilizes the qualified Twist Precision Exome Dx Panel along with the Twist Precision Prep and Enrichment Dx Kit to produce exome-enriched libraries compatible for NGS applications.

Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

Retrieved on: 
星期二, 二月 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Whole genome sequencing, Liquid biopsy, Twist Bioscience, Workflow, DNA, Circulating tumor DNA, Patient, Doctor of Philosophy, Disease, Silicon, Neoplasm, NGS, Twist, WGS, Cancer, MRD, Nucleic acid thermodynamics

The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.

Key Points: 
  • The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.
  • With exceptional accuracy and sensitivity enabled by high conversion rates, the Twist cfDNA Library Preparation Kit can help push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions.”
    The Twist cfDNA Library Preparation Kit adds to Twist’s growing portfolio of tools to support the research and development of liquid biopsy assays, which also includes the recently launched Twist cfDNA Pan-Cancer Reference Standard v2 .
  • The Twist cfDNA Library Preparation Kit can address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input.
  • The Twist cfDNA Library Preparation Kits are available in two configurations: the cfDNA Library Preparation Kit for whole genome sequencing (WGS) workflows and the Twist Library Preparation and Hyb Mix Kit for target enrichment.

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

Retrieved on: 
星期二, 二月 6, 2024
Research, General Health, Biometrics, Technology, Genetics, Health Technology, Public Relations, Investor Relations, Science, Nanotechnology, Biotechnology, Communications, Health, Other Science, Multimedia, Twist Bioscience, Workflow, Doctor of Philosophy, Exome, Learning, Silicon, NGS, Element, Fine chemical

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.
  • View the full release here: https://www.businesswire.com/news/home/20240206284355/en/
    “Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally.
  • Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here .